Our top pick for
PaySign, Inc is a specialty business services business based in the US. PaySign shares (PAYS) are listed on the NASDAQ and all prices are listed in US Dollars. PaySign employs 70 staff and has a trailing 12-month revenue of around USD$26.6 million.
|52-week range||USD$3.63 - USD$10.98|
|50-day moving average||USD$4.9429|
|200-day moving average||USD$5.5815|
|Wall St. target price||USD$5.33|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$0.11|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Valuing PaySign stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of PaySign's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
PaySign's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 48x. In other words, PaySign shares trade at around 48x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
PaySign's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$6.3 million.
The EBITDA is a measure of a PaySign's overall financial performance and is widely used to measure a its profitability.
|Revenue TTM||USD$26.6 million|
|Gross profit TTM||USD$19.2 million|
|Return on assets TTM||-6.11%|
|Return on equity TTM||-17.72%|
|Market capitalisation||USD$234.2 million|
TTM: trailing 12 months
There are currently 1.6 million PaySign shares held short by investors – that's known as PaySign's "short interest". This figure is 10.8% down from 1.8 million last month.
There are a few different ways that this level of interest in shorting PaySign shares can be evaluated.
PaySign's "short interest ratio" (SIR) is the quantity of PaySign shares currently shorted divided by the average quantity of PaySign shares traded daily (recently around 275026.42140468). PaySign's SIR currently stands at 5.98. In other words for every 100,000 PaySign shares traded daily on the market, roughly 5980 shares are currently held short.
However PaySign's short interest can also be evaluated against the total number of PaySign shares, or, against the total number of tradable PaySign shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case PaySign's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 PaySign shares in existence, roughly 30 shares are currently held short) or 0.0534% of the tradable shares (for every 100,000 tradable PaySign shares, roughly 53 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against PaySign.
Find out more about how you can short PaySign stock.
We're not expecting PaySign to pay a dividend over the next 12 months.
Over the last 12 months, PaySign's shares have ranged in value from as little as $3.63 up to $10.98. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while PaySign's is 1.5032. This would suggest that PaySign's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
PaySign, Inc. provides prepaid card products and processing services under the PaySign brand for corporate, consumer, and government applications. The company offers various services, including transaction processing, cardholder enrollment, value loading, cardholder account management, reporting, and customer service through PaySign, a proprietary platform. It also develops prepaid card solutions for corporate incentive rewards and corporate expense, per diem and travel payments, healthcare reimbursement payments, pharmaceutical co-pay assistance, donor compensation, and clinical trials; and payroll or general purpose reloadable cards, as well as gift or incentive cards. In addition, the company offers Buy and Bill programs for patients to purchase directly from physician's office or through an infusion center for physician administered therapies; payment solution for source plasma collection centers; and PaySign Premier, a demand deposit account debit card, as well as customer service center and PaySign Communications Suite services. Its principal target markets for processing services comprise prepaid card issuers, retail and private-label issuers, small third-party processors, and small and mid-size financial institutions in the United States and internationally. The company was formerly known as 3PEA International, Inc. and changed its name to PaySign, Inc. in April 2019. PaySign, Inc. is based in Henderson, Nevada.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.